$ 8.54
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of CMRX is 8.5 and suggests 0% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
